Fundraising FoxAvoro Ventures
Venture capitalActively deployingNew York · 3 people tracked
Find your way into Avoro Ventures
927 people in our graph share verified history with the Avoro Ventures team — schools, employers, funds. One of them is your warm intro.
Fund manager profile
Avoro Ventures is a venture fund manager based in New York. SEC filings show 2 venture funds on record, most recently Avoro Ventures Fund II L.P. filed July 2026.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 3 people
from public directories
What they invest in
from 4 of 4 portfolio companiesBiotech ×4Healthtech ×3Medical Devices ×2Deep Tech ×1Digital Health ×1
HQs:United States×3
Investments · 4 tracked
founders shown can be your intro pathBy year:2025 · 12021 · 23 dated
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Board seatBehzad Aghazadeh· per SEC Form D · $100M raise · filed Mar 2025
Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalVivo CapitalOrbiMed
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)in
Board seatBehzad Aghazadeh· per SEC Form D · $100M raise · filed Apr 2021
Co-investorsAndreessen HorowitzOrbiMedAvoro Capital AdvisorsMenlo VenturesRA Capital
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyAvoro Capital AdvisorsHealthCapNovo HoldingsSofinnova PartnersRA Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
3 IPOsAadi BioscienceNASDAQ: WHWKScribe TherapeuticsNASDAQ: SCTXHemab TherapeuticsNASDAQ: COAG
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Hemab Therapeutics | 4.1% | $18.00 | May 2026 | $32.4M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is Avoro Ventures located?
- Avoro Ventures is headquartered in New York, US.